Sara C. Meyer

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms

Sara C. Meyer, Matthew D. Keller, Sophia Chiu et al. · Cancer Cell · 2015 · 151 citations

Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors

Michaela Waibel, Vanessa S. Solomon, Deborah A. Knight et al. · Cell Reports · 2013 · 129 citations · Full text

Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms

Simona Stivala, Tamara Codilupi, Šime Brkić et al. · Journal of Clinical Investigation · 2019 · 122 citations · Full text

Immunology, Myeloproliferative Neoplasms, Cell Death +17

Loss of <i>Ezh2</i> synergizes with <i>JAK2</i> -V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis

Takafumi Shimizu, Lucia Kubovčáková, Ronny Nienhold et al. · The Journal of Experimental Medicine · 2016 · 113 citations · Full text

Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity

Hiroyoshi Kunimoto, Cem Meydan, Abbas Nazir et al. · Cancer Cell · 2017 · 100 citations · Full text

Chromatin, Genome Instability, Chromatin Remodeling +11